<DOC>
	<DOC>NCT00192218</DOC>
	<brief_summary>To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.</brief_summary>
	<brief_title>Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Healthy children enrolled in the target schools. Written informed consent obtained from the child's parent(s) if they agree to participate. History of severe hypersensitivity (anaphylactic response) to egg products or previous FluMist FluMist is licensed exclusively for use in healthy individuals age 549 years. Therefore children for whom annual receipt of inactivated influenza vaccine for specific medical condition(s) is recommended will not be eligible. These conditions include: Asthma, other chronic pulmonary diseases, kidney disease, metabolic disease, heart disease, or hemoglobinopathy Immunosuppression of child Severe immunosuppression of a household member Pregnancy Past history of GuillianBarre Syndrome Aspirin therapy within 1 month prior to FluMist or the anticipated use of aspirin containing products for one month after FluMist administration Administration of any inactivated vaccine within 2 weeks or any live vaccine within 4 weeks prior to receipt of FluMist Received antiinfluenza medication in the past 48 hours Fever in the past 72 hours Moderate to severe nasal congestion (inability to breathe through the nose) or acute phase URI symptoms until the congestion has improved</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>